サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1414162

びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬の世界市場レポート 2024年

Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場規模は近年力強く成長しています。2023年の44億米ドルから2024年には48億米ドルへ、CAGR8.9％で拡大します。過去の調査期間中に見られた拡大は、臨床研究の進展、規制当局の承認、患者の意識の高まりと診断法、共同イニシアチブ、標準治療の進化によるものです。

びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR7.9％で64億9,000万米ドルに成長します。予測期間中に予想される成長は、バイオマーカーの発見、免疫療法の進歩、罹患率の増加、世界の高齢化人口の増加、ヘルスケアインフラの整備、新薬へのアクセス向上などの要因によってもたらされます。予測期間に予想される重要な動向には、外来治療環境の出現、臨床試験における共同アプローチ、患者中心のケアモデルの採用、画像診断の進歩、ヘルスケアのデジタル化の進行などが含まれます。

びまん性大細胞型B細胞リンパ腫（DLBCL）の有病率の上昇は、びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の拡大を促進すると予測されています。びまん性大細胞型B細胞リンパ腫（DLBCL）は、リンパ系のB細胞から発生する非ホジキンリンパ腫の侵攻型であり、急速でびまん性の増殖が特徴です。DLBCLのために開発された治療薬は、がん細胞を効果的に標的とし、管理することによって、診断された人の予後を改善することを目的としています。注目すべきことに、米国がん協会の2023年の予測では、新たに約80,550人の非ホジキンリンパ腫患者が発生すると予測されており、治療ソリューションの進歩が緊急に必要であることを強調しています。このような罹患率の増加は、びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の成長の触媒となっています。

びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の予想成長は、個別化医療の採用増加と密接に結びついています。革新的なヘルスケアアプローチである個別化医療は、遺伝子や分子プロファイルを含む各患者の固有の特性に合わせた医療介入を行います。このアプローチは、DLBCLサブタイプの不均一性に特異的に対処する標的療法の開発を促進します。バイオマーカー主導の治療戦略とコンパニオン診断薬は、特定の治療法が有効である可能性の高い患者を同定し、全体的な治療効果を高める上で極めて重要な役割を果たします。注目すべきは、2022年に米国食品医薬品局（FDA）の医薬品評価研究センター（CDER）が37の新規分子化合物（NME）を承認し、その約34％（12のNME）が個別化医療連合（PMC）によって個別化医療に分類されたという事実です。個別化医療の採用拡大がびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場成長の重要な促進要因として浮上しています。

2023年のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬世界市場規模は北米が最大でした。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場レポートの対象地域は、アジア太平洋,西欧,東欧,北米,南米,中東,アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 市場促進要因・市場抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 市場規模と成長実績、2018～2023年
  • 市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • シスプラチン
  • カルボプラチン
  • 5-フルオロウラシル
  • ドセタキセル
  • パクリタキセル
  • メトトレキサート
  • その他
  • 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場、療法別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 標的療法
  • 免疫療法
  • 化学療法
  • その他
  • 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • その他
  • 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • クリニック
  • その他

第7章 地域および国の分析

  • 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の競合情勢
  • びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の企業プロファイル
    • Novartis AG
    • Pfizer Inc.
    • Merck &Co Inc.
    • GlaxoSmithKline plc
    • F. Hoffmann-La Roche AG

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r11672

“Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diffuse large b-cell lymphoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diffuse large b-cell lymphoma therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The diffuse large b-cell lymphoma therapeutics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Class: Cisplatin; Carboplatin; 5-fluorouracil; Docetaxel; Paclitaxel; Methotrexate; Other Drugs
  • 2) By Therapy: Targeted Therapy; Immunotherapy; Chemotherapy; Other Therapies
  • 3) By Route of Administration: Oral; Parenteral; Other Routes
  • 4) By End User: Hospitals; Clinics; Other End-Users
  • Companies Mentioned: Novartis AG; Pfizer Inc.; Merck & Co Inc.; GlaxoSmithKline plc; F. Hoffmann-La Roche AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Diffuse large B-cell lymphoma therapeutics encompass the strategies and pharmaceutical interventions employed to address and counteract diffuse large B-cell lymphoma, an aggressive subtype of non-Hodgkin lymphoma characterized by the rapid proliferation of malignant B-cells.

Key pharmaceutical categories integral to the treatment of diffuse large B-cell lymphoma include cisplatin, carboplatin, 5-fluorouracil (5-FU), docetaxel (Taxotere), paclitaxel (Taxol), methotrexate, among others. Cisplatin is a chemotherapeutic agent utilized across various malignancies due to its mechanism of disrupting cancer cell DNA, thereby impeding their proliferative capacity. In the context of lymphoma management, cisplatin is often incorporated into combination chemotherapy protocols. The therapeutic regimen encompasses a spectrum of modalities such as targeted therapy, immunotherapy, and chemotherapy, administered via oral, parenteral, and alternative routes. These treatments are typically dispensed within hospital and clinical settings.

The diffuse large B-cell lymphoma market research report is one of a series of new reports from The Business Research Company that provides diffuse large B-cell lymphoma market statistics, including the diffuse large B-cell lymphoma industry global market size, regional shares, competitors with a diffuse large B-cell lymphoma market share, detailed diffuse large B-cell lymphoma market segments, market trends, and opportunities, and any further data you may need to thrive in the diffuse large B-cell lymphoma industry. This diffuse large B-cell lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The diffuse large b-cell lymphoma therapeutics market size has grown strongly in recent years. It will grow from $4.4 billion in 2023 to $4.8 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The expansion observed during the historical period can be ascribed to advancements in clinical research, regulatory approvals, heightened patient awareness and diagnostic practices, collaborative initiatives, and the evolution of standard of care.

The diffuse large b-cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $6.49 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The anticipated growth in the forecast period is driven by factors such as biomarker discovery, advancements in immunotherapy, increasing incidence rates, a growing global aging population, development of healthcare infrastructure, and enhanced accessibility to novel drugs. Significant trends expected in the forecast period include the emergence of outpatient treatment settings, collaborative approaches in clinical trials, the adoption of patient-centric care models, advancements in diagnostic imaging, and the ongoing digitalization of healthcare.

The rising prevalence of diffuse large B-cell lymphoma (DLBCL) is anticipated to propel the expansion of the diffuse large B-cell lymphoma therapeutics market. DLBCL, an aggressive form of non-Hodgkin lymphoma originating from B-cells in the lymphatic system, is characterized by rapid and diffuse growth. The therapeutics developed for DLBCL aim to enhance outcomes for diagnosed individuals by effectively targeting and managing cancer cells. Notably, the American Cancer Society's 2023 estimates project approximately 80,550 new non-Hodgkin's lymphoma cases, underscoring the urgent need for advancements in therapeutic solutions. This increasing incidence serves as a catalyst for the growth of the diffuse large B-cell lymphoma therapeutics market.

The anticipated growth of the diffuse large B-cell lymphoma (DLBCL) therapeutics market is closely tied to the increasing adoption of personalized medicine. Personalized medicine, an innovative healthcare approach, tailors medical interventions to the unique characteristics of each patient, including genetic and molecular profiles. This approach facilitates the development of targeted therapies specifically addressing the heterogeneity of DLBCL subtypes. Biomarker-driven treatment strategies and companion diagnostics play a pivotal role in identifying patients likely to benefit from specific therapies, thus enhancing overall treatment efficacy. Noteworthy is the fact that in 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% (12 NMEs) classified as personalized medicines by the Personalized Medicine Coalition (PMC). The increasing adoption of personalized medicine emerges as a significant driver for the growth of the diffuse large B-cell lymphoma therapeutics market.

The diffuse large B-cell lymphoma (DLBCL) therapeutics market is witnessing a notable trend marked by the increasing emphasis on the development of therapeutic drugs. Key players within this market are actively engaged in the research and development of novel drugs to bolster their standing and competitiveness. A pertinent example is Bristol-Myers Squibb, a prominent US-based pharmaceutical company dedicated to drug research and development. In June 2022, the company secured approval from the US FDA for CAR T Cell Therapy Breyanzi. This approval extended the application of Breyanzi to encompass the treatment of patients with diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), and relapsed or refractory large B-cell lymphoma. Breyanzi, characterized as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, is designed to cater to a diverse patient population, including those with primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B.

A pivotal strategy employed by major players in the diffuse large B-cell lymphoma (DLBCL) therapeutics market involves the continuous development of new drugs to secure a competitive advantage. Illustratively, in June 2023, MINJUVI (tafasitamab), a product of Specialised Therapeutics Asia Pte Ltd (STA), a Singapore-based biopharmaceutical company, received approval from the Therapeutic Goods Administration (TGA). Indicated for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT), MINJUVI, in combination with lenalidomide, functions as a CD19-targeting immunotherapy, triggering an immune response against B-cell lymphoma cells. The drug has demonstrated a favorable side effect profile and achieved high response rates in patients with relapsed disease. Its approval through a provisional regulatory pathway and participation in the Modified Project Orbis initiative underscore the concerted efforts to expedite availability for Australian patients. The decision was informed by positive data from the Phase 2 L-MIND study, with ongoing approval contingent on findings from the confirmatory Phase 3 frontMIND study.

In August 2022, Ipsen, a prominent biopharmaceutical company based in France, successfully acquired Epizyme Inc. The financial details of the acquisition were not disclosed. This acquisition has proven instrumental in empowering Ipsen to diversify and enhance its oncology portfolio. Notably, the integration of Epizyme's Tazverik, a groundbreaking EZH2 inhibitor, has fortified Ipsen's commitment to providing innovative treatments. This strategic expansion has further augmented Ipsen's capabilities within the oncology sector, positioning the company as a key player in delivering advanced therapeutic solutions. Epizyme Inc., a US-based biopharmaceutical company specializing in the development and marketing of epigenetic therapies for cancer and other diseases, brought valuable expertise and assets to Ipsen through this strategic acquisition.

Major companies operating in the diffuse large b-cell lymphoma therapeutics market report are Novartis AG, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, CTI BioPharma Corp., Celltrion Healthcare Co Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences Inc., Seagen Inc., Kite Pharma Inc., ADC Therapeutics SA, Bayer AG, Erytech Pharma SA, Xencor Inc., Denovo Biopharma LLC, Calithera Biosciences Inc., IMV Inc., Biogen Inc., Autolus Therapeutics plc, Allogene Therapeutics Inc., Spectrum Pharmaceuticals Inc., AstraZeneca PLC, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Aptevo Therapeutics Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Celgene Corporation, Eli Lilly and Company, Sanofi SA, Seattle Genetics Inc., Karyopharm Therapeutics Inc., TG Therapeutics Inc., MorphoSys AG,

North America was the largest region in the global diffuse large B-cell lymphoma therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diffuse large b-cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the diffuse large b-cell lymphoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The diffuse large B-cell lymphoma therapeutics market consists of revenues earned by entities by providing R-CHOP (rituximab (Rituxan), cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Oncovin), and prednisone therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The diffuse large B-cell lymphoma therapeutics market also includes sales of diagnostic devices, radiation therapy equipment, surgical instruments, and devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Diffuse Large B-cell Lymphoma Therapeutics Market Characteristics

3. Diffuse Large B-cell Lymphoma Therapeutics Market Trends And Strategies

4. Diffuse Large B-cell Lymphoma Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Diffuse Large B-cell Lymphoma Therapeutics Market Size and Growth

  • 5.1. Global Diffuse Large B-cell Lymphoma Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Diffuse Large B-cell Lymphoma Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Diffuse Large B-cell Lymphoma Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Diffuse Large B-cell Lymphoma Therapeutics Market Segmentation

  • 6.1. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Cisplatin
  • Carboplatin
  • 5-fluorouracil
  • Docetaxel
  • Paclitaxel
  • Methotrexate
  • Other Drugs
  • 6.2. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
  • Other Therapies
  • 6.3. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • Other Routes
  • 6.4. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Other End-Users

7. Diffuse Large B-cell Lymphoma Therapeutics Market Regional And Country Analysis

  • 7.1. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market

  • 8.1. Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Diffuse Large B-cell Lymphoma Therapeutics Market

  • 9.1. China Diffuse Large B-cell Lymphoma Therapeutics Market Overview
  • 9.2. China Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Diffuse Large B-cell Lymphoma Therapeutics Market

  • 10.1. India Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Diffuse Large B-cell Lymphoma Therapeutics Market

  • 11.1. Japan Diffuse Large B-cell Lymphoma Therapeutics Market Overview
  • 11.2. Japan Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Diffuse Large B-cell Lymphoma Therapeutics Market

  • 12.1. Australia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Diffuse Large B-cell Lymphoma Therapeutics Market

  • 13.1. Indonesia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market

  • 14.1. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market Overview
  • 14.2. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Diffuse Large B-cell Lymphoma Therapeutics Market

  • 15.1. Western Europe Diffuse Large B-cell Lymphoma Therapeutics Market Overview
  • 15.2. Western Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Diffuse Large B-cell Lymphoma Therapeutics Market

  • 16.1. UK Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Diffuse Large B-cell Lymphoma Therapeutics Market

  • 17.1. Germany Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Diffuse Large B-cell Lymphoma Therapeutics Market

  • 18.1. France Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Diffuse Large B-cell Lymphoma Therapeutics Market

  • 19.1. Italy Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Diffuse Large B-cell Lymphoma Therapeutics Market

  • 20.1. Spain Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Diffuse Large B-cell Lymphoma Therapeutics Market

  • 21.1. Eastern Europe Diffuse Large B-cell Lymphoma Therapeutics Market Overview
  • 21.2. Eastern Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Diffuse Large B-cell Lymphoma Therapeutics Market

  • 22.1. Russia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Diffuse Large B-cell Lymphoma Therapeutics Market

  • 23.1. North America Diffuse Large B-cell Lymphoma Therapeutics Market Overview
  • 23.2. North America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Diffuse Large B-cell Lymphoma Therapeutics Market

  • 24.1. USA Diffuse Large B-cell Lymphoma Therapeutics Market Overview
  • 24.2. USA Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Diffuse Large B-cell Lymphoma Therapeutics Market

  • 25.1. Canada Diffuse Large B-cell Lymphoma Therapeutics Market Overview
  • 25.2. Canada Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Diffuse Large B-cell Lymphoma Therapeutics Market

  • 26.1. South America Diffuse Large B-cell Lymphoma Therapeutics Market Overview
  • 26.2. South America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market

  • 27.1. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Diffuse Large B-cell Lymphoma Therapeutics Market

  • 28.1. Middle East Diffuse Large B-cell Lymphoma Therapeutics Market Overview
  • 28.2. Middle East Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Diffuse Large B-cell Lymphoma Therapeutics Market

  • 29.1. Africa Diffuse Large B-cell Lymphoma Therapeutics Market Overview
  • 29.2. Africa Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Diffuse Large B-cell Lymphoma Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Diffuse Large B-cell Lymphoma Therapeutics Market Competitive Landscape
  • 30.2. Diffuse Large B-cell Lymphoma Therapeutics Market Company Profiles
    • 30.2.1. Novartis AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Pfizer Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. GlaxoSmithKline plc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. F. Hoffmann-La Roche AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Diffuse Large B-cell Lymphoma Therapeutics Market Competitive Benchmarking

32. Global Diffuse Large B-cell Lymphoma Therapeutics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Diffuse Large B-cell Lymphoma Therapeutics Market

34. Diffuse Large B-cell Lymphoma Therapeutics Market Future Outlook and Potential Analysis

  • 34.1 Diffuse Large B-cell Lymphoma Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Diffuse Large B-cell Lymphoma Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Diffuse Large B-cell Lymphoma Therapeutics Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer